Robert Kossmann, MD

SAN DIEGO — In this video exclusive from ASN Kidney Week, nephrologists underscore the beneficial potential of using of high-volume hemodiafiltration therapy in the United States.

Since the arrival of SARS-CoV-2 on U.S. shores, patients who receive dialysis for end-stage kidney disease have been at heightened risk. The first reported patient to die of COVID-19 was a 50-year-old man who received hemodialysis treatment at a Seattle-area dialysis facility.

Since the arrival of SARS-CoV-2 on U.S. shores, patients who receive dialysis for end-stage kidney disease have been at heightened risk. The first reported patient to die of COVID-19 was a 50-year-old man who received hemodialysis treatment at a Seattle-area dialysis facility.